Cardiosonic Ltd.

Sonivie Ltd.

Or Shabtay

Ariel Sverdlik

Yehuda Zadok

Dalit Shav

Benny Dilmoney

Daniel Naor

Ofek Admon

Charles S Carignan

Iris Szwarcfiter

Maya Rosenstein

Talia Cohen Keizman

Avital Schauder

Krishna Rocha-Singh

Marina Dubinsky

Jonathan Yalom

Ronen Neeman

Giora Beit-Yaakov

Lilah Marziano

Lilah Hemi

According to some embodiments there is provided a method for controlling a treatment effect on blood vessel tissue during an ultrasonic treatment, the method comprising positioning an ultrasonic transducer device in the blood vessel lumen; controlling a treatment effect by controlling fluid flow, wherein controlling comprises deploying a fluid restrictor at a location relative to the transducer effective to block at least a portion of fluid flowing upstream, downstream or adjacent the transducer. According to some embodiments there is provided an ultrasonic transducer device sized for placement in a body lumen, and comprising a fluid restrictor effective to block at least a portion of fluid flowing upstream, downstream or adjacent the transducer. In some embodiments, the fluid is blood.

Ultrasound transducer and uses thereof

Some embodiments relate to a method of reducing excess mucosa production and/or secretion in the respiratory tract, comprising: introducing into a respiratory tract lumen a device configured for damaging nerve tissue or blocking neural conduction in the surroundings of said lumen, the device comprising a plurality of energy emitters; positioning the energy emitters of the device inside the lumen at a distance from walls of the lumen; and activating the energy emitters to emit energy suitable to damage the nerve tissue enough to suppress parasympathetic nerve activity which causes excess mucosa production and/or secretion.

Devices and methods for reducing parasympathetic nerve activity in patients with a respiratory syndrome

Disclosed herein is a therapeutically active agent usable in the treatment of pulmonary arterial hypertension (PAH), for use in the treatment of pulmonary arterial hypertension, as well as methods of treating PAH, said treatment and methods comprising administering such an active agent and effecting pulmonary artery denervation in the subject. In some aspects, a sub-therapeutically effective amount of the active agent is administered. In some aspects, the method is devoid of administering such an active agent for at least one month subsequent to the denervation. Further disclosed is a method of treating PAH comprising determining a responsiveness of the subject to at least one therapeutically active agent usable in treating PAH; and effecting pulmonary artery denervation in a subject responsive to the active agent(s).

Pulmonary hypertension treatment

The present invention, in some embodiments thereof, relates to methods and/or apparatus for measuring the effectiveness of a renal denervation treatment. In some embodiments, a method for determining effectiveness of the denervation treatment comprises tracking at least one of arterial wall movement, arterial blood flow rate, arterial blood flow velocity, blood pressure and arterial diameter at one or more selected locations in the renal artery over time, and assessing the effectiveness of said renal denervation treatment according to results obtained by tracking.

Method and/or apparatus for measuring renal denervation effectiveness

Some embodiments relate to a method of reducing excess mucosa production and/or secretion in the respiratory tract, comprising: introducing into the lumen of the trachea or the lumen of the bronchi a device configured for damaging nerve tissue or blocking neural conduction in the surroundings of the lumen; and activating the device to damage the nerve tissue enough to suppress parasympathetic nerve activity which causes the excess mucosa production and/or secretion.

There is provided in accordance with an exemplary embodiment of the invention a method of treating a subject suffering from a nerve related disorder, the method comprising causing a damage region to one or both of a lumen wall or nearby surrounding tissues, the damage region encompassing a volume having dimensions of less than about 6.8 mm in a substantially radial direction, less than about 5.8 mm in a direction substantially tangential to the lumen, less than about 10 mm in a substantially axial direction, the damage region being located no closer than about 0.2 mm from an inner wall of the lumen, the damage region comprises of greater than about 60% of collagen denatured tissue.

Tissue treatment

The present invention, in some embodiments thereof, relates to a devices and methods for intravascular denervation and assessment thereof and, more particularly, but not exclusively, to devices and methods for renal denervation. Some embodiments of the invention relate to an intravascular catheter configured for ultrasonic ablation of the tissue, comprising a plurality of piezoelectric transceivers. In some embodiments, an intravascular distancing device is provided, the device adapted for obtaining at least a minimal distance between an ultrasound emitting element and a tissue, such as the blood vessel wall. Some embodiments of the invention relate to assessment of renal sympathetic denervation (RSD) treatment effectiveness. Some embodiments of the invention relate to processing echo of signals, such as processing of signals to characterize physical and/or mechanical properties of the blood vessel.

Devices and methods for renal denervation and assessment thereof

There is provided in accordance with an exemplary embodiment of the invention a method and/or a device of treating tissue near a first lumen comprising inserting an energy emission element into a second lumen and delivering energy in an amount sufficient to cause one or more spaced apart areas of tissue damage at preselected locations in tissue near the first lumen. There is also provided a method and/or a device for treating a carotid artery wall, for example, to reduce signal conduction. There is also provided a method and/or a device for treating a wall of a lumen in a limb, for example, to increase blood flow. There is also provided a method and/or a device for treating a wall of a heart, for example, to stop abnormal signal propagation.

An ultrasonic transceiver device for producing ultrasonic beams comprises a body vibratable at ultrasonic frequencies and an extensive surface for beam emanation, the device configured to produce an unfocused, or alternatively a focused, power beam for thermal tissue damage, the power beam being produced by vibration over the body of the transceiver and emanating from the extent of the surface, whereby the extensive surface becomes subject to convective cooling when immersed in a fluid by a chimney effect set up by said unfocused beam.

Ultrasound transceiver and cooling thereof

There is provided in accordance with an exemplary embodiment of the invention an ultrasound transducer for intrabody medical therapy comprising; an element adapted to transmit ultrasound energy; at least two electrodes configured to apply a voltage across at least some volume of the element; and a gas bubble containment area adapted to retain the gas bubble when in blood.

Ultrasound transducer

There is provided in accordance with an exemplary embodiment of the invention an ultrasound catheter for intrabody medical therapy comprising; an element adapted to emit ultrasound energy; at least two electrodes configured to apply a voltage across at least some volume of the element; and a gas bubble containment area adapted to retain the gas bubble when in blood.

Growing community of inventors

Kibbutz Farod, Israel

Or Shabtay